Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

BSI-201 and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Study:

Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Rationale:

BSI-201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving BSI-201 together with temozolomide and radiation therapy may kill more tumor cells.

Purpose:

This phase I/II trial is studying the side effects and best dose of BSI-201 when given together with temozolomide with or without radiation therapy and to see how well it works in treating patients with newly diagnosed malignant glioma.

Study Status: Recruiting

Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: BSI-201
Drug: temozolomide
Procedure: 3-dimensional conformal radiation therapy
Procedure: intensity-modulated radiation therapy
Phase 1/Phase 2

Verified by National Cancer Institute (NCI) April, 2008

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00589576

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Jaishri O. Blakeley, MD., Study Chair
Stuart A. Grossman, MD.,

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site